Body Mass Index and Prognosis of Patients With Stage II/III Gastric Cancer After Curative Gastrectomy: Completion of Perioperative Adjuvant Chemotherapy May Be a Confounding Factor.

The mOS in patients with high BMI (≥ 20.3 kg/m 2 ) who received complete PAC (≥ 6 cycles, n = 655) did not reach statistical significance when compared with that in patients with low BMI and complete PAC (79 months, n = 265, P = 0.145), but was significantly better than that in patients with high BMI and incomplete PAC (56 months, n = 1,042, P < 0.001), and in patients with low BMI and incomplete PAC (34 months, n = 548, P < 0.001) ( Figure 4 ).

also in 111,027 other papers